



Antimicrobial Stewardship in Critical Care

Guest Editors:

Dr. David Cluck

Department of Pharmacy
Practice, Bill Gatton College of
Pharmacy, East Tennessee State
University, Johnson City, TN
37614, USA

Dr. Jennifer Tharp

Department of Pharmacy,
Johnson City Medical Center,
Johnson City, TN 37604, USA

Dr. Leslie Hamilton

Health Science Center College of
Pharmacy, University of
Tennessee, Knoxville, TN 37920,
USA

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

The aftermath of the COVID-19 pandemic highlighted the importance antimicrobial stewardship in critically ill patients, as these patients are often most likely to receive broad-spectrum antimicrobial therapy. During the pandemic, stewardship was often not a focal point for hospitalized patients; however, many institutions are now reprioritizing antimicrobial stewardship efforts, including in critically ill patients. This Special Issue aims to capture impactful manuscripts in content areas including but not limited to:

1. Examining the intersection of COVID-19 and antimicrobial stewardship;
2. Lessons learned from the pandemic as it pertains to stewardship;
3. Novel antimicrobial stewardship approaches in the critically ill patient population;
4. Stewardship strategies with new antimicrobial therapies;
5. De-escalation strategies in the ICU.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)